Skip to main content
. 2016 May 9;7(23):33765–33782. doi: 10.18632/oncotarget.9260

Figure 2. Cisplatin increased IL-10 production and endocytosis in LPS-activated DCs.

Figure 2

A. BMDCs were treated with LPS (100 ng/mL) in the absence or presence of cisplatin at various concentrations (1, 2 and 5 μg/mL) for 18 h. The amounts of TNF-α, IL-12p70, and IL-10 in the culture supernatants were measured by ELISA. The data are shown as the mean ± SD (n = 3 samples). One representative plot out of three independent experiments is shown. *p < 0.05 and ***p < 0.001 compared to treatment with LPS alone. B. Intracellular TNF-α, IL-12p70 and IL-10 levels in CD11c+ DCs. One representative plot from three independent experiments is shown. C. The cells were incubated with FITC-dextran either at 37°C for 30 min or at 4°C as a control. Endocytic capacity was determined by assessing the endocytosis of FITC-dextran by flow cytometry (left panel). The bar graphs (right panel) indicate the mean ± SD (n = 3 samples) of the percentage of dextran-FITC-positive CD11c+ cells. The results are representative of three independent experiments. The values shown represent the mean ± SD (n = 3 samples). **p < 0.01 or ***p < 0.001 compared to DCs treated with LPS alone.